SMMT Form 4: Yu Xia reports 533,617-share private placement buy

Rhea-AI Filing Summary

Summit Therapeutics (SMMT) reported an insider transaction by director Yu Xia. On 10/21/2025, she acquired 533,617 shares of common stock at $18.74 per share in a private placement pursuant to a definitive agreement, anticipated to close on or about 10/23/2025. After the transaction, 32,057,147 shares were beneficially owned indirectly through Akeso, Inc. Dr. Xia disclaims beneficial ownership of Akeso’s holdings except to the extent of her pecuniary interest.

Insights

Equity Capital Markets Analyst

Insider participated in issuer private placement, adding cash and increasing indirect holdings.

Summit Therapeutics Inc. (SMMT) disclosed a director-affiliated purchase of 533,617 common shares at $18.74 per share in a private placement under a definitive agreement dated October 21, 2025. This implies cash proceeds to the issuer of approximately $9,999,982.58 from this reporting person’s portion, with closing anticipated on or about October 23, 2025.

The reporting person’s beneficial ownership following the transaction is 32,057,147 shares held indirectly through **Akeso, Inc.** The filing notes the shares are directly owned by Akeso, and the reporting person disclaims beneficial ownership except to the extent of pecuniary interest. This reflects continued alignment and a sizable indirect stake.

Key dependencies include the closing of the private placement as anticipated and any associated conditions in the definitive agreement. Items to watch: actual closing on or about October 23, 2025, any subsequent filings detailing aggregate proceeds and participants, and updates to ownership disclosures related to Akeso’s holdings.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Xia Yu

(Last) (First) (Middle)

C/O SUMMIT THERAPEUTICS INC.

601 BRICKELL KEY DRIVE, SUITE 1000

(Street)

MIAMI FL 33131

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Summit Therapeutics Inc. [ SMMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/21/2025		P		533,617(1)	A	$18.74	32,057,147	I	Akeso, Inc.(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of October 21, 2025, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person and certain other parties at a purchase price of $18.74 per share. The transaction is anticipated to close on or about October 23, 2025.

2. Akeso is the direct beneficial owner of the shares of the Issuer's Common Stock. Dr. Xia is a stockholder and exercises the right to vote approximately 25.96% of Akeso's ordinary shares, and serves as chairwoman, president and chief executive officer of Akeso. Dr. Xia disclaims beneficial ownership of the shares of Issuer's Common Stock beneficially owned by Akeso, except to the extent of her pecuniary interest.

Remarks:

	/s/ Adam Finerman, as Attorney-in-Fact for Yu Xia	10/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did SMMT director Yu Xia report on Form 4?

She reported acquiring 533,617 shares of Summit Therapeutics common stock at $18.74 per share on 10/21/2025.

How were the SMMT shares acquired by Yu Xia?

They were acquired in a private placement pursuant to a definitive agreement; closing was anticipated on or about 10/23/2025.

What is the reported ownership after the transaction?

Beneficial ownership is 32,057,147 shares, held indirectly through Akeso, Inc.

What is Yu Xia’s relationship to Summit Therapeutics (SMMT)?

She is a Director of Summit Therapeutics Inc.

What is Yu Xia’s relationship to Akeso, Inc.?

She is a stockholder who exercises the right to vote approximately 25.96% of Akeso’s ordinary shares and serves as chairwoman, president and CEO of Akeso.

Does Yu Xia claim full beneficial ownership of Akeso’s SMMT shares?

No. She disclaims beneficial ownership of Akeso’s SMMT shares except to the extent of her pecuniary interest.